BLCM — Bellicum Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $0.95m
- -$4.96m
- $1.50m
Brief: Bellicum Announces Update On Clinical Hold Of U.S. BPX-501 Studies
Bellicum's cancer drug trials on clinical hold, shares tumble
Brief: Bellicum Pharmaceuticals Announces Clinical Hold On BPX-501 Clinical Trials In U.S.
Brief: Bellicum Enters Into Agreement With Oxford Finance To Borrow $35 Mln - SEC Filing
Brief: Bellicum reports qtrly earnings per share loss $0.71
Brief: Bellicum Pharmaceuticals enters a cancer research grant contract with cancer prevention and research institute of Texas
Brief: Bellicum Pharmaceuticals qtrly loss per share $0.74
Brief: Bellicum Pharmaceuticals files for mixed shelf offering of upto $150 mln
Brief: Bellicum Pharmaceuticals files prospectus relating to disposition of up to about 5 million shares
Brief: Bellicum Pharmaceuticals qtrly loss per share $0.80
Brief: Bellicum Pharmaceuticals says public offering of 5 mln shares priced at $12 each
Brief: Bellicum Pharmaceuticals announces proposed public offering of 5 mln common stock
Brief: Bellicum Pharmaceuticals posts Q4 net loss $19.9 mln
Brief: Bellicum Pharmaceuticals says dosed first patient with BPX-601
Brief: Bellicum announces appointment of Rick Fair as CEO
Brief: Adaptimmune, Bellicum Pharma collaborate to evaluate next-generation T-cell therapies
Brief: Bellicum presents clinical results to date of BPX-501 pediatric program
Brief: Bellicum Pharmaceuticals posts Q3 net loss $17.7 million
Brief: Bellicum reports Q3 net loss per share $0.66